- $131.57bn
- $146.80bn
- €44.29bn
- 95
- 65
- 57
- 85
Annual cashflow statement for Sanofi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 12,294 | 6,223 | 8,371 | 5,400 | 5,560 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -8,001 | -105 | 20 | 1,249 | 1,185 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -325 | 1,409 | -707 | 413 | -615 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 7,418 | 10,522 | 10,526 | 10,258 | 8,914 |
| Capital Expenditures | -2,083 | -2,043 | -2,201 | -2,906 | -3,195 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5,702 | -5,255 | 126 | -3,294 | -1,212 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 3,619 | -7,298 | -2,075 | -6,200 | -4,407 |
| Financing Cash Flow Items | -44 | -48 | -99 | -63 | -50 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -6,485 | -7,056 | -5,821 | -8,052 | -5,763 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4,488 | -3,817 | 2,638 | -4,026 | -1,269 |